CXCL8 and pancreatic neoplasm: To next determine the requirement of active IL-8 for human pancreatic cancer cell CM-induced myotube atrophy, we pretreated CM with a blocking antibody to IL-8 or an isotype control IgG antibody and then added it to 4-day differentiated C2C12 myotubes for 48 h.